CTIS2024-511887-10-00进行中（未招募）1 期
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer - D6132C00001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Documented evidence of extensive stage SCLC (ES-SCLC), Participants must be considered suitable to receive a platinum-based chemotherapy regimen, combined with durvalumab, as first-line treatment for ES-SCLC, No prior exposure to immune-mediated therapy, Life expectancy =12 weeks, ECOG 0 or 1 at enrolment
排除标准
- •Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy, Has a paraneoplastic syndrome (PNS) of autoimmune systemic steroids or immunosuppressive agents) or has a clinical symptomatology suggesting worsening of PNS, Active infection including tuberculosis, HIV, hepatitis B and C, Active or prior documented autoimmune or inflammatory disorders, Uncontrolled intercurrent illness, including but not limited to interstitial lung disease
研究者
相似试验
进行中（未招募）
1 期
A study investigating what potential benefits adding AZD2811 might have to the current standard of care maintenance therapy of durvalumab in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) who have not had any treatment yet for their cancer.EUCTR2020-004091-18-ESAstraZeneca AB100
进行中（未招募）
1 期
A study investigating what potential benefits adding AZD2811 might have to the current standard of care maintenance therapy of durvalumab in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) who have not had any treatment yet for their cancer.First-line patients with extensive disease small-cell lung cancer (SCLC)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004091-18-PLAstraZeneca AB100
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of MOR00208 used in combination with Idelalisib in Patients with Relapsed or Refractory ChronicLymphocytic Leukemia or Small Lymphocytic Lymphoma who have been previously Treated with Bruton's Tyrosine Kinase(BTK) Inhibitor.Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10003910Term: B-cell small lymphocytic lymphoma NOSSystem Organ Class: 100000004864EUCTR2015-002915-14-ITMORPHOSYS AG120
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of MOR00208 used in combination with Idelalisib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma who have been previously Treated with Bruton’s Tyrosine Kinase (BTK) Inhibitor.Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaMedDRA version: 18.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10003910Term: B-cell small lymphocytic lymphoma NOSSystem Organ Class: 100000004864EUCTR2015-002915-14-FRMorphoSys AG120
进行中（未招募）
不适用
A Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as treatment re-challenge in Patients, who have Non-Small Cell Lung Cancer (NSCLC)on small cell lung cancerMedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005157-31-ITASTRAZENECA